Bio-Rad Laboratories

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.

About BIO.B

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,700
Employees7,700
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,700
Employees7,700

BIO.B Key Statistics

Market cap
8.48B
Market cap8.48B
Price-Earnings ratio
-12.94
Price-Earnings ratio-12.94
Dividend yield
Dividend yield
Average volume
233.40
Average volume233.40
High today
$315.08
High today$315.08
Low today
$314.40
Low today$314.40
Open price
$315.08
Open price$315.08
Volume
88.00
Volume88.00
52 Week high
$359.22
52 Week high$359.22
52 Week low
$225.29
52 Week low$225.29

Stock Snapshot

Bio-Rad Laboratories(BIO.B) stock is priced at $314.40, giving the company a market capitalization of 8.48B. It carries a P/E multiple of -12.94.

During the trading session on 2025-11-15, Bio-Rad Laboratories(BIO.B) shares reached a daily high of $315.08 and a low of $314.40. At a current price of $314.40, the stock is 0.0% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 88, compared to an average daily volume of 233.4.

The stock's 52-week range extends from a low of $225.29 to a high of $359.22.

The stock's 52-week range extends from a low of $225.29 to a high of $359.22.

BIO.B News

Simply Wall St 3d
Is Bio-Rad’s Third Quarter Net Loss and Share Buyback Shaping the Investment Case for BIO?

Bio-Rad Laboratories recently reported third quarter 2025 earnings, with sales of US$653 million and a shift from net income to a net loss of US$341.9 million,...

Is Bio-Rad’s Third Quarter Net Loss and Share Buyback Shaping the Investment Case for BIO?
Simply Wall St 5d
Bio-Rad Laboratories: Assessing Valuation Following Q3 Loss and Share Buyback Completion

Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also...

Bio-Rad Laboratories: Assessing Valuation Following Q3 Loss and Share Buyback Completion
TipRanks 5d
Top Executive Sells Bio-Rad Laboratories Stock in Major Transaction

New insider activity at Bio-Rad Laboratories ( (BIO) ) has taken place on November 10, 2025. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can...

Analyst ratings

57%

of 7 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

People also own

Based on the portfolios of people who own BIO.B. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.